Oral Contraceptive Pill (OCP) Pharmacogenomics

NCT06334315

Status	RECRUITING
Phase	Phase 4
Sponsor	Yale University
Enrollment	700 participants

Key Eligibility Criteria

Inclusion (9)

- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Female, aged 18-45 years old
- In good general health as evidenced by medical history and no need for regular intensive medical interventions (e.g., inpatient admissions, surgical treatments). The Principal Investigator will be responsible for determining good general health for potential participants with complicated medical histories.
- Ability to take oral medication and be willing to adhere to the oral contraceptive pill (DSG/EE) regimen

... and 4 more (see full listing online)

Exclusion (27)

- Currently taking any known CYP3A inducers/inhibitors (e.g., rifampin, carbamazepine, ketoconazole, St. John's wort)43
- Any medical conditions that affect liver function (e.g., hepatitis, cirrhosis)
- Contraindications to estrogen-containing contraception (based on category 3 or 4 recommendations in the CDC MEC guidelines42)
- Current breast cancer or personal history of breast cancer
- Severe decompensated cirrhosis

... and 22 more (see full listing online)

Locations (2 total)

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Yale University, New Haven, Connecticut, United States